-Sarepta extends Research License and Option Agreement for ImmTOR® in Duchenne Muscular Dystrophy and certain Limb-Girdle Muscular Dystrophies-
-Selecta to receive a $2 million payment from Sarepta extending their option periods under the agreement to Q1 2023-
Read more at globenewswire.com